

University of Groningen

Vitreous advanced glycation endproducts and alpha-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls

Fokkens, Bernardina T.; Mulder, Douwe; Schalkwijk, Casper G.; Scheijen, Jean L.; Smit, Andries J.; Los, Leonoor

Published in:
Plos one

DOI:
[10.1371/journal.pone.0173379](https://doi.org/10.1371/journal.pone.0173379)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Fokkens, B. T., Mulder, D. J., Schalkwijk, C. G., Scheijen, J. L., Smit, A. J., & Los, L. I. (2017). Vitreous advanced glycation endproducts and alpha-dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls. *Plos one*, 12(3). DOI: 10.1371/journal.pone.0173379

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Vitreous advanced glycation endproducts and α -dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls

Bernardina T. Fokkens^{1,2,3*}, Douwe J. Mulder¹, Casper G. Schalkwijk⁴, Jean L. Scheijen⁴, Andries J. Smit^{1,2}, Leonoor I. Los^{3,5}

1 Department of Internal Medicine, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands, **2** Research Institute GUIDE, Graduate School of Medical Sciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands, **3** Department of Ophthalmology, University of Groningen, University Medical Center Groningen (UMCG), the Netherlands, **4** Laboratory for Metabolism and Vascular Medicine, Maastricht University, Department of Experimental Internal Medicine, Maastricht, the Netherlands, **5** W.J. Kolff Institute, Graduate School of Medical Sciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands

* bt.fokkens@umcg.nl



OPEN ACCESS

Citation: Fokkens BT, Mulder DJ, Schalkwijk CG, Scheijen JL, Smit AJ, Los LI (2017) Vitreous advanced glycation endproducts and α -dicarbonyls in retinal detachment patients with type 2 diabetes mellitus and non-diabetic controls. PLoS ONE 12 (3): e0173379. doi:10.1371/journal.pone.0173379

Editor: Andreas Wedrich, Medizinische Universitat Graz, AUSTRIA

Received: November 18, 2016

Accepted: February 20, 2017

Published: March 6, 2017

Copyright: © 2017 Fokkens et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data are available on the website of DataverseNL (<http://hdl.handle.net/10411/20841>).

Funding: BTF was supported financially by Stichting Blindenhulp, The Netherlands (<http://www.blindenhulp.nl/>). This organization had no role in the design or conduct of this research.

Competing interests: Prof. Dr. A.J. Smit is founder and shareholder of Diagnostics Technologies BV (the Netherlands) which is the company that has developed the autofluorescence reader that was

Abstract

Purpose

Advanced glycation endproducts (AGEs) and their precursors α -dicarbonyls are implicated in the progression of diabetic retinopathy. The purpose of this study was to assess AGEs and α -dicarbonyls in the vitreous of patients with type 2 diabetes mellitus (T2DM) with early stages or absence of diabetic retinopathy.

Methods

We examined vitreous samples obtained during vitrectomy from 31 T2DM patients presenting themselves with rhegmatogenous retinal detachment and compared these to 62 non-diabetic rhegmatogenous retinal detachment patients, matched on age, estimated glomerular filtration rate, smoking, intra-ocular lens implantation, and proliferative vitreoretinopathy. AGEs (pentosidine, N^ε-(carboxymethyl)lysine, N^ε-(carboxyethyl)lysine, and 5-hydro-5-methylimidazolone) and α -dicarbonyls (3-deoxyglucosone, methylglyoxal, and glyoxal) were measured by ultra performance liquid chromatography or high performance liquid chromatography. Skin autofluorescence was measured by the AGE Reader.

Results

Mean age was 64 ± 7.6 years for T2DM patients and 63 ± 8.1 years for controls. For T2DM patients, median diabetes duration was 2.2 (0.3–7.4) years. Non-proliferative diabetic retinopathy was present in 1 patient and classified as absent or background retinopathy in 30 patients. Vitreous levels of pentosidine (2.20 vs. 1.59 $\mu\text{mol/mol}$ lysine, $p = 0.012$) and 3-deoxyglucosone (809 vs. 615 nmol/L , $p = 0.001$) were significantly elevated in T2DM

used in this study to assess skin accumulation of AGEs. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

patients compared to controls. Other AGEs and α -dicarbonyls in the vitreous were not significantly different. There was a trend for increased skin autofluorescence in T2DM patients as compared to controls ($p = 0.07$).

Conclusions

Pentosidine and 3-deoxyglucosone concentrations were increased in the vitreous of rhegmatogenous retinal detachment patients with a relatively short duration of diabetes compared to non-diabetic rhegmatogenous retinal detachment patients.

Introduction

Advanced glycation endproducts (AGEs) are thought to be involved in the pathogenesis of many age-related diseases, such as diabetes mellitus, atherosclerosis, cataract and Alzheimer's disease. AGEs are formed by glycation and oxidation of free amino groups of proteins, lipids and nucleic acids. This metabolic process is complex and heterogeneous, yielding numerous different AGE adducts, such as pentosidine, N^ε-(carboxymethyl)lysine (CML), N^ε-(carboxyethyl)lysine (CEL) and 5-hydro-5-methylimidazolone (MG-H1)[1].

In diabetes, prolonged hyperglycemia and oxidative stress accelerate the accumulation of some AGEs. Besides via the classical Maillard reaction, AGEs are formed through the reaction of α -dicarbonyls, such as 3-deoxyglucosone (3-DG), methylglyoxal (MGO), and glyoxal (GO), with protein amino groups[2]. Accumulation of AGEs also strongly depends on tissue turnover because AGEs are mainly irreversibly linked to tissue proteins. Therefore, tissues with slow turnover (such as the skin, lens, and cartilage) capture decades-long glycaemia. In tissues with fast turnover (such as plasma, epidermis and mucosa), AGEs accumulate to a lesser extent since they are rapidly broken down to AGE peptides or free AGEs, which are excreted through the kidney[3].

AGEs promote tissue dysfunction *in vitro* and *in vivo* by altering protein structure, by cross-linking of long lived molecules and through binding to the receptor for advanced glycation endproducts (RAGE)[1,4]. Both α -dicarbonyls and AGEs have been linked to diabetic complications and have been postulated to play a pathological role in the development of these complications[5–7].

Several studies have shown elevated serum and vitreous AGE levels in diabetic retinopathy (DR)[8,9]. Furthermore, AGEs have been suggested to influence the transition of retinopathy from the non-proliferative to the proliferative state[10]. However, vitreous AGE levels have mainly been measured in DR patients with proliferative diabetic retinopathy (PDR) or diabetic macular edema (DME) and have always been compared to non-diabetic controls undergoing vitrectomy for several eye conditions. Currently, it is unclear whether vitreous AGE levels are already elevated in diabetes before the development of PDR or DME.

The aim of the present study was to investigate several AGEs (pentosidine, CML, CEL and MG-H1) and α -dicarbonyls (3-DG, MGO, and GO) in the vitreous of type 2 diabetes patients (T2DM) without PDR in relation to non-diabetic controls. We examined vitreous samples obtained during vitrectomy from T2DM patients with a rhegmatogenous retinal detachment (RRD) and compared these to non-diabetic controls with comparable retinal detachment severity. Pentosidine is a cross-linking AGE which is thought to serve as an adequate marker for overall AGE levels[11,12]. In addition, DR could be influenced by AGEs through RAGE

activation and, therefore, we also analysed several AGEs which have been shown to interact with RAGE[13,14].

Materials and methods

Study population

Participants were initially recruited in a prospective cohort study in which 410 RRD patients were included between November 2013 and August 2015 in our tertiary referral center (NTR4289). All patients gave written informed consent, and the study was approved by the Medical Ethics Committee of the University Medical Center Groningen and adhered to the Declaration of Helsinki. The present cross-sectional analysis is a sub-study hereof that addresses the secondary explicated research aim mentioned above. In this sub-study, 31 T2DM patients were 1:2 matched on age[15], estimated glomerular filtration rate (eGFR), smoking[16], intra-ocular lens implantation[17], and proliferative vitreoretinopathy (PVR) [17,18] to 62 non-diabetic patients. Diabetes mellitus was defined by criteria from the American Diabetes Association[19] or twice measured values of HbA1c \geq 48 mmol/mol. Absence of diabetes and prediabetes in the non-diabetic patients was ascertained by absence of a history of diabetes, absence of anti-diabetic medication usage, and by presence of a normal HbA1c level ($<$ 42mmol/mol) and a normal non-fasting glucose level (\leq 7.8 mmol/l).

Clinical data and general characteristics were obtained by chart review and questionnaires. The following exclusion criteria applied to all subjects: known renal disease with impairment of renal function (eGFR $<$ 60 ml/min), dialysis treatment, history of renal transplantation[20], current infection or active inflammatory disease[21]. Presence of DR was established by fundus photography or by ophthalmic examination by an ophthalmologist. Both pre- and postoperatively, patients were examined accurately by fundoscopy. When DR was not specifically mentioned in latest notes of the ophthalmologist or retinal surgeon, it was assumed that DR could be classified as absent or minimal background DR.

Standard laboratory assessments

Non-fasting venous blood was collected by venipuncture. Plasma glucose, HbA1c, serum creatinine and C-reactive protein (CRP) were measured using standard procedures. Renal function was evaluated by eGFR calculated by the *Modification of Diet in Renal Disease* (MDRD) formula: $eGFR = 186 \times [\text{serum creatinine } (\mu\text{mol/L}) \times 0.0113]^{-1.154} \times \text{age}^{-0.203}$ ($\times 0.742$ for women). CRP was measured to ensure that no active infection or inflammatory disease was present.

Vitreous samples and measurement of AGEs

At the start of the vitrectomy procedure, undiluted vitreous samples were collected from the midvitreous by aspirating the vitreous manually through a syringe connected to the vitrectome. The samples were frozen within 15–30 minutes and stored at -80°C until further use. Measurement methods of AGEs and α -dicarbonyls have been described in detail elsewhere: pentosidine was measured using high performance liquid chromatography (HPLC) with a fluorescence detector[22]; lysine and protein-bound and free CML, CEL, and MG-H1 were measured using ultra performance liquid chromatography tandem mass spectrometry (UPLC MS/MS)[23]; derivatized 3-DG, MGO, and GO were analyzed by UPLC MS/MS [24].

Skin autofluorescence

Skin autofluorescence (SAF) was measured on the left forearm using the AGE Reader (DiagnOptics Technologies BV, Groningen, The Netherlands), a non-invasive desk-top device using the characteristic fluorescent properties of certain AGEs to estimate the level of AGE accumulation in the skin. Technical details concerning the optical technique have been extensively described elsewhere[25].

Ophthalmic characteristics

Characteristics of retinal detachment were determined during surgery. Surface area of detached retina in relation to total retinal surface was scored in quartiles. Proliferative vitreoretinopathy (PVR) was graded A to C, according to the Retina Society PVR classification[26]. When PVR grade A was present, patients were classified as 'non-PVR'; when PVR grades B or C were present, patients were classified as 'PVR'.

Statistical analysis

Sample size was based on previously reported pentosidine concentrations in diabetes and control patients[27] in which the effect size was 1.1. Based on $\alpha = 0.05$ and power = 80%, the minimum number of subjects needed in this study was 25 T2DM patients and 50 control patients. Data obtained from each sample group were presented as mean and standard deviation (SD) or as median and interquartile range (IQR). Differences between T2DM patients and controls were tested using χ^2 tests for categorical variables, t-tests for normally distributed continuous variables and Mann-Whitney U tests for remaining variables. Spearman correlation coefficients were used for a correlation analysis. Statistical significance was accepted at $p < 0.05$. Statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA).

Results

Clinical characteristics of the study population stratified for T2DM patients and controls are shown in Table 1. There was no significant difference in clinical characteristics between the two subgroups, except for body mass index, non-fasting glucose, and HbA1c. Furthermore, there was no significant difference in intra-operatively present characteristics of retinal detachment (i.e. surface area of detachment, PVR grade and detachment duration), indicating comparable disease severity between the subgroups.

Characteristics of T2DM patients

Thirty-one T2DM patients (age range: 43–84 years) participated in the study, including 6 who were newly diagnosed with diabetes at inclusion. Median diabetes duration, as recorded by the general practitioner, was 2.2 (0.3–7.4) years. Maximum diabetes duration was 26.3 years. Two patients were treated with insulin only, 3 patients with a combination of insulin and metformin, 10 patients with metformin and 6 patients with a combination of 2 oral anti-diabetics. The remaining 10 patients were not treated medically or had only received lifestyle advice before inclusion. In the T2DM subgroup, 61% of the patients used anti-hypertensives and 48% of the patients used statins. Microvascular complications were present in 2 patients: 1 patient had diabetic neuropathy and 1 patient had non proliferative DR. In the remaining 30 patients, DR was classified as absent or minimal background retinopathy. Six patients had a history of myocardial infarction or cerebrovascular accident.

Table 1. Clinical characteristics of the study population.

Characteristic	T2DM (n = 31)	Control (n = 62)	P Value
Age, y	64 \pm 7.6	63 \pm 8.1	NA
Gender, male, %	74.2	79.0	0.599
BMI, kg/m²	27 \pm 3.9	25 \pm 3.4	< 0.001
Duration of diabetes, y	2.2 (0.3–7.4)	-	NA
Systolic blood pressure, mmHg	131 (120–145)	135 (130–145)	0.463
Current smoker, %	12.9	11.3	NA
Intra ocular lens implantation, %	45.2	46.8	NA
Surface area of detachment >50%, %	45.2	50.0	0.764
PVR grade B & C, %	29.0	17.7	NA
Detachment duration, days	9 (7–18)	8 (5–16)	0.191
Non fasting glucose, mmol/L	7.1 (6.5–9.4)	5.9 (5.6–6.3)	< 0.001
HbA1c, mmol/mol	50 (45–60)	37 (35–39)	< 0.001
eGFR, ml/min	91 (75–106)	85 (75–99)	NA
Skin autofluorescence, AU	2.5 (2.2–3.0)	2.2 (2.1–2.6)	0.070

For categorical variables, data are displayed as percentages and p-values are based on χ^2 tests. For normally distributed continuous variables, data are given as mean \pm SD and p-values are based on t-tests. For remaining variables, data are shown as median (interquartile range) and p-values are based on Mann-Whitney U tests. Note: no statistical tests were performed on the parameters on which both groups were matched. T2DM, type 2 diabetes mellitus; NA, not applicable; BMI, body mass index; PVR, proliferative vitreoretinopathy; eGFR, estimated glomerular filtration rate.

doi:10.1371/journal.pone.0173379.t001

Characteristics of controls

Sixty-two non-diabetic patients (age range: 44–83 years) formed the control subgroup. In this group, 27% of the patients used anti-hypertensives and 15% of the patients used statins. Furthermore, 4 patients had a history of myocardial infarction or cerebrovascular accident. Medication use of both anti-hypertensives ($p = 0.002$) and statins ($p < 0.001$), but not history of macrovascular events ($p = 0.058$), was significantly lower in the control group compared to T2DM.

Vitreous AGEs and α -dicarbonyls

Biochemical characteristics of the vitreous stratified for T2DM patients and controls are shown in Table 2. Correlation analysis between AGEs and α -dicarbonyls on the one hand and general characteristics (like age, gender, HbA1c, and eGFR) on the other hand revealed some weak to moderate correlations. In the T2DM subgroup, 3-DG ($r = 0.592$, $p = 0.001$) was associated with HbA1c, while pentosidine ($r = -0.022$, $p = 0.908$) and the other AGEs and α -dicarbonyls were not. Additionally, SAF was not associated with any of the vitreous AGEs and α -dicarbonyls in the T2DM subgroup. Further results of the correlation analysis are not shown.

Comparison of AGE levels between the subgroups showed significantly increased vitreous protein-bound pentosidine in T2DM patients (2.20 vs. 1.59 $\mu\text{mol/mol}$ lysine, $p = 0.012$). Both protein-bound and free CML, CEL, and MG-H1 were not significantly different.

Comparison of α -dicarbonyl levels between the subgroups showed significantly increased vitreous 3-DG concentrations in T2DM patients (809 vs. 615 nmol/L, $p < 0.001$). Vitreous MGO and GO were not significantly different.

Discussion

This study addressed the accumulation of several AGEs and their potential precursors (α -dicarbonyls) in a unique body compartment: the vitreous body. Our results show that both

Table 2. Biochemical characteristics of the vitreous.

Characteristic	T2DM (n = 31)	Control (n = 62)	P Value
Lysine, mmol/L	0.56 (0.37–1.52)	0.66 (0.41–1.13)	0.993
Protein-bound AGEs			
Pentosidine, $\mu\text{mol/mol lysine}$	2.20 (1.59–3.20)	1.59 (1.18–2.52)	0.012
CML, $\mu\text{mol/mol lysine}$	255 (199–298)	223 (179–318)	0.222
CEL, $\mu\text{mol/mol lysine}$	127 \pm 66.3	122 \pm 64.3	0.717
MG-H1, $\mu\text{mol/mol lysine}$	750 (452–1264)	734 (383–1383)	0.883
Free AGEs			
CML, nmol/L	78 (57–92)	77 (58–95)	0.839
CEL, nmol/L	71 \pm 21.7	65 \pm 21.1	0.198
MG-H1, nmol/L	145 (100–234)	181 (133–247)	0.156
α -dicarbonyls			
3-DG, nmol/L	809 (714–1043)	615 (531–764)	< 0.001
MGO, nmol/L	231 (197–289)	234 (199–274)	0.961
GO, nmol/L	466 (330–747)	431 (246–675)	0.563

For normally distributed continuous variables, data are given as mean \pm SD and p-values are based on t-tests. For other variables, data are shown as median (interquartile range) and p-values are based on Mann-Whitney U tests. T2DM, type 2 diabetes mellitus; CML, N^ε-(carboxymethyl)lysine; CEL, N^ε-(carboxyethyl)lysine; MG-H1, 5-hydro-5-methylimidazolone; 3-DG, 3-deoxyglucosone; MGO, methylglyoxal; GO, glyoxal.

doi:10.1371/journal.pone.0173379.t002

protein-bound pentosidine and 3-DG were significantly elevated in T2DM patients as compared to non-diabetic controls matched for age, eGFR, smoking, intra-ocular lens implantation and PVR. However, the levels of other protein-bound AGEs (CML, CEL, and MG-H1), free AGEs (CML, CEL, and MG-H1), and other α -dicarbonyls (MGO and GO) did not differ between the two groups.

It has been proposed that AGEs and α -dicarbonyls may be considered as major initiators of retinal microvascular complications in T2DM. Enhanced reactive oxygen species (ROS) generation induced by AGE-RAGE interaction appears to be a likely cause of pericyte loss, the earliest histopathological hallmark of DR. Furthermore, AGEs are considered to stimulate vascular endothelial growth factor (VEGF) expression in pericytes, which is considered to promote neovascularization in DR[28,29]. Moreover, it has been suggested that AGEs might contribute to persistent central vitreo-retinal adhesions[17], which leads to vitreoretinal traction that can exacerbate the course of DR.

Several reports have shown elevated levels of pentosidine (measured by HPLC or enzyme-linked immunosorbent assay (ELISA)) in the vitreous of patients with PDR compared to non-diabetic controls[27,30,31]. However, one study[32] reported that the significantly higher levels in the T2DM group disappeared when levels of pentosidine (measured by HPLC) were corrected for vitreous protein concentration. This is important because this may suggest that the increase in pentosidine concentration might simply reflect alterations in the blood-retinal barrier in DR. Furthermore, the aging vitreous consists of areas of synchysis and syneresis[33,34], which could lead to sampling errors while taking a vitreous biopsy.

In the current study, pentosidine concentrations expressed per mmol of lysine residues were significantly elevated in T2DM patients. Since lysine is used as a proxy for the total amount of protein available for AGE modification[35,36] expression of AGEs per mmol of lysine provides an adjustment for differences in protein amount in the vitreous biopsy. The current study is also of value because it shows that pentosidine levels are already elevated in T2DM patients without extensive microvascular damage to the retina.

Concerning 3-DG in diabetes, no previous reports have addressed its level in other tissues than plasma. In plasma, several studies have reported elevated levels of 3-DG in both T1DM and T2DM[37–39], and 3-DG has been suggested to play a role in the development of vascular complications[6,40]. In agreement with these previous reports, the current study shows elevated 3-DG levels in the vitreous of T2DM patients.

Skin autofluorescence, as an extensively validated marker of skin accumulation of AGEs, tended to be greater in T2DM patients compared to controls. This is in line with previous publications[41,42] in which skin autofluorescence was increased in patients with diabetes, particularly in case of complications. The difference in skin fluorescence in our study was just not significant, which is probably due to the short diabetes duration and limited numbers of patients and complications.

Our observation that other protein-bound AGEs (CML, CEL, and MG-H1) and α -dicarbonyls (MGO and GO) were not elevated in the vitreous of T2DM patients compared to controls was unexpected. Of these AGEs and α -dicarbonyls, only protein-bound CML has been previously investigated in the vitreous of patients with diabetes. In that study[10], CML was found to be increased in PDR patients compared to controls. In addition, increased levels of several protein-bound AGEs and α -dicarbonyls have been found in the plasma of patients with diabetes[43]. Furthermore, in most studies, accumulation of AGEs in skin and serum are strongly associated with the severity of diabetic complications[44].

Since free AGEs are breakdown products of protein-bound AGEs, the absence of elevated levels of free AGEs indicates that the lack of differences in protein-bound CML, CEL, and MG-H1 in the current study is not a result of differences in degradation of these products. To illustrate, when degradation of proteins in the vitreous would be present to a greater extent in T2DM patients, one would expect that free AGEs would be elevated in these patients.

Several factors should be considered in interpreting the noted dissimilarities of our results with previous research. First, our study group consisted of T2DM patients with a relatively short duration of diabetes and without PDR. Second, it is important to distinguish between the results of measurements in different body compartments. It is not correct to directly compare results of plasma values to vitreous values because of differences in tissue turnover. Moreover, the vitreous is unique in its supply of nutrients and exposure to plasma components because of the blood-retinal barrier. Third, methodological differences in AGE measurements may contribute to discrepancies in results, especially when AGE levels are not expressed per protein content of the samples. Further, limited blood contamination in the vitreous samples of 4 diabetes and 5 control patients could have influenced our results. However, previous research indicated that limited blood contamination did not confound AGE measurements in the vitreous of RRD patients. Additionally, several frequently used drugs (such as anti-hypertensives [45] and statins[46]) have been shown to inhibit AGE formation *in vitro* and *in vivo*[47]. Although the influence of these drugs on AGE accumulation in human tissues with slow turnover has to be further elucidated, the more frequent use of anti-hypertensives and statins in T2DM patients may have masked our results by lowering AGE levels in these patients. Finally, our current study size may be too small to detect differences in other AGEs than pentosidine, since our sample size calculation was based on previously reported pentosidine values only.

Overall, it is difficult to provide a concise explanation as to why most of the measured AGEs and α -dicarbonyls in the current study were similar in the vitreous of the two patient groups while only pentosidine and 3-DG were elevated in the diabetes group. Correlation analysis showed a moderate correlation of 3-DG with HbA1c in the diabetes subgroup, indicating a relation with glycaemic control. This observation suggests an influence of mechanisms outside the eye on vitreous AGE content. Whether this association is causal, or merely a reflection of the underlying disease process cannot be determined by the current study. The generally

weak relations between AGE levels in tissues with slow turnover and plasma stress the need for differentiating the behaviour of different AGEs and α -dicarbonyls within and between different tissue compartments. Another recent illustration of this need for differentiating AGE behaviour is given in a study which showed a close correlation of SAF and plasma pentosidine, but not of plasma CML and CEL, with arterial pulse wave velocity[48].

Because of its cross-sectional design, the current study could not address the causal role of AGEs in DR. Prospective studies are needed to investigate the role of AGEs in the development of DR and their potential to influence the transition of retinopathy from the non-proliferative to the proliferative state.

The major strength of the current study is that several AGEs and α -dicarbonyls were measured with state-of-the-art techniques based on UPLC MS/MS. Furthermore, only patients with RRD (with and without T2DM) were investigated in this study. This is an advantage to investigate the influence of diabetes on AGE accumulation in the vitreous per se. Moreover, it is usually hard to find a homogeneous diabetes group without PDR and a homogeneous control group for which vitreous samples are available since vitrectomy procedures are only performed in limited patient groups. On the other hand, the inclusion of only RRD patients is a limitation of this study. Care must be taken in extrapolating the results to T2DM patients and controls without RRD since the blood-retinal barrier may be disrupted to varying degrees in RRD[49,50]. Furthermore, our results concerning free AGEs and α -dicarbonyls should be interpreted with caution. Since the exact behaviour of free AGEs and α -dicarbonyls in the vitreous is unknown, the results concerning these products could be subject to sampling errors.

In summary, this study shows that levels of protein-bound pentosidine and 3-DG were increased in the vitreous of T2DM patients with a relatively short duration of diabetes. Since AGEs have been suggested to be involved in the development of DR, this study provides a basis for future studies in DR by showing an overview of several specific AGEs and α -dicarbonyls in the vitreous of early diabetes and non-diabetic subjects. Prospective studies with standardized AGE measurements in diabetes patients are needed to further elucidate the exact role of different AGEs and α -dicarbonyls in the development of DR.

Acknowledgments

The authors wish to thank Eveline A Huiskamp, Gina Postma, and Victor W Renardel de Lavalette for conducting the vitreous sampling.

Author Contributions

Conceptualization: BTF DJM CGS AJS LIL.

Data curation: BTF.

Formal analysis: BTF.

Funding acquisition: BTF LIL.

Investigation: BTF JLS.

Methodology: BTF DJM CGS JLS AJS LIL.

Project administration: BTF LIL.

Resources: CGS AJS LIL.

Supervision: AJS LIL.

Validation: BTF JLS.

Visualization: BTF.

Writing – original draft: BTF.

Writing – review & editing: DJM CGS JLS AJS LIL.

References

1. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? *J Gerontol A Biol Sci Med Sci*. 2010; 65: 963–75. doi: [10.1093/gerona/gdq074](https://doi.org/10.1093/gerona/gdq074) PMID: [20478906](https://pubmed.ncbi.nlm.nih.gov/20478906/)
2. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem J*. 1999; 344 Pt 1: 109–16.
3. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. *Nat Rev Endocrinol*. 2011; 7: 526–39. doi: [10.1038/nrendo.2011.74](https://doi.org/10.1038/nrendo.2011.74) PMID: [21610689](https://pubmed.ncbi.nlm.nih.gov/21610689/)
4. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. *Redox Biol*. Elsevier; 2014; 2: 411–29.
5. Odani H, Shinzato T, Matsumoto Y, Usami J, Maeda K. Increase in three α , β -dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. *Biochem Biophys Res Commun*. 1999; 256: 89–93. doi: [10.1006/bbrc.1999.0221](https://doi.org/10.1006/bbrc.1999.0221) PMID: [10066428](https://pubmed.ncbi.nlm.nih.gov/10066428/)
6. Ogawa S, Nakayama K, Nakayama M, Mori T, Matsushima M, Okamura M, et al. Methylglyoxal is a predictor in type 2 diabetic patients of intima-media thickening and elevation of blood pressure. *Hypertension*. 2010; 56: 471–476. doi: [10.1161/HYPERTENSIONAHA.110.156786](https://doi.org/10.1161/HYPERTENSIONAHA.110.156786) PMID: [20644005](https://pubmed.ncbi.nlm.nih.gov/20644005/)
7. Lu J, Randell E, Han Y, Adeli K, Krahn J, Meng QH. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. *Clin Biochem*. The Canadian Society of Clinical Chemists; 2011; 44: 307–11.
8. Sebag J, Buckingham B, Charles MA, Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. *Arch Ophthalmol (Chicago, Ill 1960)*. 1992; 110: 1472–6. Available: <http://www.ncbi.nlm.nih.gov/pubmed/1417549>
9. Stitt AW, Moore JE, Sharkey JA, Murphy G, Simpson DA, Bucala R, et al. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. *Invest Ophthalmol Vis Sci*. 1998; 39: 2517–23. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9856760 PMID: [9856760](https://pubmed.ncbi.nlm.nih.gov/9856760/)
10. Choudhuri S, Dutta D, Sen A, Chowdhury IH, Mitra B, Mondal LK, et al. Role of N- ϵ -carboxy methyl lysine, advanced glycation end products and reactive oxygen species for the development of nonproliferative and proliferative retinopathy in type 2 diabetes mellitus. *Mol Vis*. 2013; 19: 100–13. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3559098&tool=pmcentrez&rendertype=abstract> PMID: [23378723](https://pubmed.ncbi.nlm.nih.gov/23378723/)
11. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. *J Biol Chem*. 1991; 266: 11654–60. PMID: [1904867](https://pubmed.ncbi.nlm.nih.gov/1904867/)
12. Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. *Biochem J*. 2000; 350 Pt 2: 381–7. Available: <http://www.ncbi.nlm.nih.gov/pubmed/10947951>
13. Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, et al. Advanced glycation end product recognition by the receptor for AGEs. *Structure*. 2011; 19: 722–32. doi: [10.1016/j.str.2011.02.013](https://doi.org/10.1016/j.str.2011.02.013) PMID: [21565706](https://pubmed.ncbi.nlm.nih.gov/21565706/)
14. Xue J, Ray R, Singer D, Böhme D, Burz DS, Rai V, et al. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. *Biochemistry*. 2014; 53: 3327–35. doi: [10.1021/bi500046t](https://doi.org/10.1021/bi500046t) PMID: [24824951](https://pubmed.ncbi.nlm.nih.gov/24824951/)
15. van Deemter M, Ponsioen TL, Bank RA, Snabel JMM, van der Worp RJ, Hooymans JMM, et al. Pentosidine accumulates in the aging vitreous body: a gender effect. *Exp Eye Res*. Elsevier Ltd; 2009; 88: 1043–50.
16. van Waateringe RP, Slagter SN, van der Klauw MM, van Vliet-Ostapchouk J V., Graaff R, Paterson AD, et al. Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study. *Eur J Clin Invest*. 2016; 46: 481–90. doi: [10.1111/eci.12627](https://doi.org/10.1111/eci.12627) PMID: [27002914](https://pubmed.ncbi.nlm.nih.gov/27002914/)
17. van Deemter M, Bank RA, Vehof J, Hooymans JMM, Los LI. Factors associated with pentosidine accumulation in the human vitreous. *Retina*. 2016;

18. Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. *Exp Eye Res.* 2006; 82: 807–15. doi: [10.1016/j.exer.2005.09.022](https://doi.org/10.1016/j.exer.2005.09.022) PMID: [16364297](https://pubmed.ncbi.nlm.nih.gov/16364297/)
19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care.* 2003; 26 Suppl 1: S5–20.
20. Stinghen AEM, Massy ZA, Vlassara H, Striker GE, Boullier A. Uremic Toxicity of Advanced Glycation End Products in CKD. *J Am Soc Nephrol.* 2016; 27: 354–70. doi: [10.1681/ASN.2014101047](https://doi.org/10.1681/ASN.2014101047) PMID: [26311460](https://pubmed.ncbi.nlm.nih.gov/26311460/)
21. de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CGM, Bijl M, et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. *Arthritis Res Ther. BioMed Central Ltd;* 2011; 13: R205.
22. Scheijen JLJM, van de Waarenburg MPH, Stehouwer CDA, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2009; 877: 610–4. doi: [10.1016/j.jchromb.2009.01.022](https://doi.org/10.1016/j.jchromb.2009.01.022) PMID: [19188098](https://pubmed.ncbi.nlm.nih.gov/19188098/)
23. Hanssen NMJ, Engelen L, Ferreira I, Scheijen JLJM, Huijberts MS, van Greevenbroek MMJ, et al. Plasma levels of advanced glycation endproducts N ϵ -(carboxymethyl)lysine, N ϵ -(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. *J Clin Endocrinol Metab.* 2013; 98: E1369–73. doi: [10.1210/jc.2013-1068](https://doi.org/10.1210/jc.2013-1068) PMID: [23780372](https://pubmed.ncbi.nlm.nih.gov/23780372/)
24. Scheijen JL, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. *Clin Chem Lab Med.* 2014; 52: 85–91. doi: [10.1515/ccclm-2012-0878](https://doi.org/10.1515/ccclm-2012-0878) PMID: [23492564](https://pubmed.ncbi.nlm.nih.gov/23492564/)
25. Mulder DJ, Van De Water T, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. *Diabetes Technol Ther.* 2006; 8: 523–35. doi: [10.1089/dia.2006.8.523](https://doi.org/10.1089/dia.2006.8.523) PMID: [17037967](https://pubmed.ncbi.nlm.nih.gov/17037967/)
26. Thompson J. Proliferative vitreoretinopathy. Ryan S, Retina ST Louis Mosby. 2001; 2287–2316.
27. Matsumoto Y, Takahashi M, Chikuda M, Arai K. Levels of mature cross-links and advanced glycation end product cross-links in human vitreous. *Jpn J Ophthalmol.* 2002; 46: 510–7. PMID: [12457909](https://pubmed.ncbi.nlm.nih.gov/12457909/)
28. Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. *Curr Diabetes Rev.* 2005; 1: 93–106. PMID: [18220586](https://pubmed.ncbi.nlm.nih.gov/18220586/)
29. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature.* 2001; 414: 813–20. doi: [10.1038/414813a](https://doi.org/10.1038/414813a) PMID: [11742414](https://pubmed.ncbi.nlm.nih.gov/11742414/)
30. Matsumoto Y, Takahashi M, Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. *Jpn J Ophthalmol.* 2002; 46: 406–12. PMID: [12225819](https://pubmed.ncbi.nlm.nih.gov/12225819/)
31. Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, et al. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. *Diabetes Res Clin Pract.* 2003; 61: 93–101. PMID: [12951277](https://pubmed.ncbi.nlm.nih.gov/12951277/)
32. Tome CC, Silva MVDR, Rodriguez-Garcia J, Rodriguez-Segade S, Sanchez-Salorio M, Tomé CC, et al. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment. *Graefe's Arch Clin Exp Ophthalmol = Albr von Graefes Arch für Klin und Exp Ophthalmol.* 2005; 243: 1272–6.
33. Los LI, van der Worp RJ, van Luyn MJA, Hooymans JMM. Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. *Invest Ophthalmol Vis Sci.* 2003; 44: 2828–33. PMID: [12824219](https://pubmed.ncbi.nlm.nih.gov/12824219/)
34. Bishop PN, Holmes DF, Kadler KE, McLeod D, Bos KJ. Age-related changes on the surface of vitreous collagen fibrils. *Invest Ophthalmol Vis Sci.* 2004; 45: 1041–1046. PMID: [15037566](https://pubmed.ncbi.nlm.nih.gov/15037566/)
35. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. *J Biol Chem.* 1989; 264: 21597–21602. Available: <http://www.ncbi.nlm.nih.gov/pubmed/2513322> PMID: [2513322](https://pubmed.ncbi.nlm.nih.gov/2513322/)
36. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. *J Biol Chem.* 1986; 261: 4889–94. Available: <http://www.ncbi.nlm.nih.gov/pubmed/3082871> PMID: [3082871](https://pubmed.ncbi.nlm.nih.gov/3082871/)
37. Lal S, Kappler F, Walker M, Orchard TJ, Beisswenger PJ, Szwegold BS, et al. Quantitation of 3-deoxyglucosone levels in human plasma. *Arch Biochem Biophys.* 1997; 342: 254–60. doi: [10.1006/abbi.1997.0117](https://doi.org/10.1006/abbi.1997.0117) PMID: [9186486](https://pubmed.ncbi.nlm.nih.gov/9186486/)

38. Nakayama K, Nakayama M, Iwabuchi M, Terawaki H, Sato T, Kohno M, et al. Plasma alpha-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease patients. *Am J Nephrol*. 2008; 28: 871–878. doi: [10.1159/000139653](https://doi.org/10.1159/000139653) PMID: [18547947](https://pubmed.ncbi.nlm.nih.gov/18547947/)
39. Maessen DE, Hanssen NM, Scheijen JL, van der Kallen CJ, van Greevenbroek MM, Stehouwer CD, et al. Post-Glucose Load Plasma α -Dicarbonyl Concentrations Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: The CODAM Study. *Diabetes Care*. 2015; 38: 913–20. doi: [10.2337/dc14-2605](https://doi.org/10.2337/dc14-2605) PMID: [25710921](https://pubmed.ncbi.nlm.nih.gov/25710921/)
40. Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwegold BS. Alpha-oxoaldehyde metabolism and diabetic complications. *Biochem Soc Trans*. 2003; 31: 1358–63. PMID: [14641063](https://pubmed.ncbi.nlm.nih.gov/14641063/)
41. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. *Diabetes Care*. 2006; 29: 2654–9. doi: [10.2337/dc05-2173](https://doi.org/10.2337/dc05-2173) PMID: [17130200](https://pubmed.ncbi.nlm.nih.gov/17130200/)
42. Meerwaldt R, Graaff R, Oomen PHN, Links TP, Jager JJ, Alderson NL, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. *Diabetologia*. 2004; 47: 1324–30. doi: [10.1007/s00125-004-1451-2](https://doi.org/10.1007/s00125-004-1451-2) PMID: [15243705](https://pubmed.ncbi.nlm.nih.gov/15243705/)
43. Nowotny K, Jung T, Hohn A, Weber D, Grune T, Höhn A, et al. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. *Biomolecules*. 2015; 5: 194–222. doi: [10.3390/biom5010194](https://doi.org/10.3390/biom5010194) PMID: [25786107](https://pubmed.ncbi.nlm.nih.gov/25786107/)
44. Monnier VM, Sell DR, Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. *Ann N Y Acad Sci*. 2005; 1043: 567–81. doi: [10.1196/annals.1333.065](https://doi.org/10.1196/annals.1333.065) PMID: [16037280](https://pubmed.ncbi.nlm.nih.gov/16037280/)
45. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. *Int Heart J*. 2008; 49: 681–689. PMID: [19075484](https://pubmed.ncbi.nlm.nih.gov/19075484/)
46. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Takeuchi M, Maeda S, et al. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). *Oxid Med Cell Longev*. 2010; 3: 304–307. doi: [10.4161/oxim.3.5.13069](https://doi.org/10.4161/oxim.3.5.13069) PMID: [21150335](https://pubmed.ncbi.nlm.nih.gov/21150335/)
47. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. *Pathol Biol (Paris)*. 2006; 54: 405–19.
48. van Eupen MGA, Schram MT, van Sloten TT, Scheijen J, Sep SJS, van der Kallen CJ, et al. Skin Autofluorescence and Pentosidine Are Associated With Aortic Stiffening: The Maastricht Study. *Hypertens (Dallas, Tex 1979)*. 2016; 68: 956–63.
49. Schroder S, Muether PS, Caramoy A, Hahn M, Abdel-Salam M, Diestelhorst M, et al. Anterior chamber aqueous flare is a strong predictor for proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. *Retina*. 2012; 32: 38–42. doi: [10.1097/IAE.0b013e3182173753](https://doi.org/10.1097/IAE.0b013e3182173753) PMID: [21765375](https://pubmed.ncbi.nlm.nih.gov/21765375/)
50. Amann T, Nguyen NX, Kuchle M. Tyndallometry and cell count in the anterior chamber in retinal detachment. *Klin Monbl Augenheilkd*. 1997; 210: 43–47. doi: [10.1055/s-2008-1035012](https://doi.org/10.1055/s-2008-1035012) PMID: [9206733](https://pubmed.ncbi.nlm.nih.gov/9206733/)